Index

Note: page numbers in italics refer to figures; those in bold to tables or boxes.

4-2-1 rule, maintenance fluids 217, 217, 353
22q11 deletion syndrome see velocardiofacial syndrome
1234-78910 rule, tracheal tube length 315
1500 rule, insulin therapy 222
1234-78910 rule, tracheal tube length 315
22q11 deletion syndrome
4-2-1 rule, maintenance fluids 217, 217, 353

1004–5
airway management problems 320, 660–1
acid–base balance, renal function 162, 163
acid-base disturbances
congenital heart disease 602, 630, 638
end-stage liver disease 685–6
end-stage lung disease 709–10
liver transplantation 691–2
malignant hyperthermia 1166
pyloric stenosis 732–3
see also metabolic acidosis
dl-acid glycoprotein (AGP) 170, 171, 198
acid maltase deficiency. 1040–3
acnephalus syndrome 817–19
acnephaly 814
ACh test 986
actin, cardiac muscle contraction 86–7
actin, cardiac muscle contraction 86–7
activated partial thromboplastin time (aPTT) 231, 231–2
acogulation factor assays 231–2
lupus anticoagulant 231
neutrophils 212, 212, 229
point-of-care testing 234
prophylactic testing 233, 278, 279
reference range 1312
active compression-decompression device (ACD) 261
acrosart, standardized patient 1227–9
adenotonsillectomy 781
adenoid hyperplasia 1296
adenoidectomy 781
adenoids 303
adenosine
cardiac arrest 265
dosing 1296
re-entrant supraventricular tachycardias 954
adenotonsillectomy 781–5
coeagulation status 783
coagulation status 783
coagulation status 783
coagulation status 783
coagulation status 783
coagulation status 783
craniofacial disorders 782, 825
discharge criteria 367
Down syndrome 782–3, 995
intraoperative management 783–5, 784
obstructive sleep apnea 781–3, 876–7, 879
outpatient anesthesiology 875–8, 879
postoperative analgesia 784–5, 850–1, 886
postoperative complications 785, 877
preoperative assessment 331, 781–2
preoperative coagulation tests 233
sickle cell disease 783
adenyl cyclase (AC) 83, 85
adjuvants, local anesthetic 202, 422–3
administrative data 1241–2
adolescents 520–38
alcohol and drug use 521
bariatric surgery 535, 535–6, 536
case study 537–8
chronic diseases 522–34
cigarette smoking 522
confidentiality issues 4–5
decision-making capacity 3, 3

chronic kidney disease (CKD; chronic renal failure) 165–7
dialysis 750–4
etiology 166
preoperative assessment 277renal transplantation 683
see also end-stage renal disease; renal failure
chronic lung disease (CLD)
ex-premature infants 496
premature infants 478, 479
chronotropy 951

CIOMS (Council for International Organizations of Medical Science) 50
Circle of Willis 127–8
circulation
CPR 260–2
fetal see fetal circulation
maternal 79, 79
pediatric intensive care 949–60
regulation of vascular tone 88–91, 89
single ventricle/parallel 624–8
transitional 79, 79, 103–4
see also pulmonary circulation; systemic circulation
circulatory overload, transfusion-associated (TACO) 250
circumcision 745
cirrhosis, pathophysiology 683, 683–6
cisatracurium 194–6
citalopram 1296
Clathrin 91
citrate-phosphate-dextrose (CPD) 241

citrate toxicity, transfusion-associated 251

citrate-phosphate-dextrose-adrenaline (CPDA-1) 241
citrate toxicity, transfusion-associated 251
Clara cells 100
clathrin 91
clearance 161–2
allometric scaling 169, 169
drugs 171
intravenous agents 181
muscle relaxants 193
opioids 189
cleft lip and palate reconstruction 822–3
airway management 320
developing countries 1146

genetics 813, 823
LAHSHAL code 822–3
myringotomy tube placement 779
premature infants 484
range of malformations 822
cleft lip and palate 822–3
airway management 840–1
anesthetic management 840, 840
history 810
pharyngeal flap 833, 833
postoperative management 840–1
preoperative evaluation 840
surgical procedures 832, 832–3
clevudine 63
clindamycin 1296
clinical data 1241–2
clinical trials 40–59
authorship of papers 46, 57
budgeting issues 57–8

close-out and termination stage 58–9
common impediments 41–2
concept protocol 54
core groups 42–3
data management 55–7
defined 41, 11
document preparation 55–7
ethical aspects 49–53
ethical review and approval 50, 50–1
exclusion 58
feasibility assessment 54–5
funding 46–7
informed consent document 57
initial design stage 54–5
outcome measures 44–5
phases of testing new drugs 47, 47–8
protocol development stage 55–8
protocols 55, 56
revenue planning 55
registration 58
research question 42
safety monitoring plan 57
sample size and power 45
single center vs. multicenter 45–6
stages 53–9, 54
study design 42–5
timing 43–4
see also research
clinic procedures, anesthesia and sedation for

cleft lip and palate 840–1

preoperative evaluation 840
postoperative management 840–1

preoperative evaluation 344

ear surgery 779–80
metabolism 172, 172–3, 173, 190–1
pharmacokinetics 189, 190–1
code sets 1272
correction, research participants 53
cognitive impairment adolescents 533–4
extremely premature infants 493, 493
parental presence at induction 343
premedication 344
spinal surgery 662
see also developmental delay;
neurodevelopmental outcomes
cold agglutinins 1304
Coke’s formula, modified 314
coiled solutions, neonates 216
colonic atresias 153
common carotid artery, development 74
Common Rule (45 CFR 46) 50, 51
communication 1284

critical issues for effective 1284–3, 1284
closed-loop 1283, 1283
defined 1283
during hand-offs see hand-offs

high-fidelity simulation 1227–9
with ICU 947
mnemonics 364, 364, 365, 1283
with PACU 363–4
performance skills 1223
problems, frequency 1284
strategies 1283
compartment syndrome 914
complement, serum 1303

cleft lip and palate reconstruction 840–1
anesthetic management 840, 840
history 810
pharyngeal flap 833, 833
postoperative management 840–1
preoperative evaluation 840
surgical procedures 832, 832–3
clevudine 63
clindamycin 1296
clinical data 1241–2
clinical trials 40–59
authorship of papers 46, 57
budgeting issues 57–8

close-out and termination stage 58–9
common impediments 41–2
concept protocol 54
core groups 42–3
data management 55–7
defined 41, 11
document preparation 55–7
ethical aspects 49–53
ethical review and approval 50, 50–1
exclusion 58
feasibility assessment 54–5
funding 46–7
informed consent document 57
initial design stage 54–5
outcome measures 44–5
phases of testing new drugs 47, 47–8
protocol development stage 55–8
protocols 55, 56
revenue planning 55
registration 58
research question 42
safety monitoring plan 57
sample size and power 45
single center vs. multicenter 45–6
stages 53–9, 54
study design 42–5
timing 43–4
see also research
clinic procedures, anesthesia and sedation for
cloacal exstrophy 740, 741
cloacal extrophy 742
clozapine 116, 116
clonidine
emergency agitation 736
epidural 202, 423, 862, 863
premedication 289, 344
cloning, electronic records 1276
Closed Claims Project, ASA 1153, 1242–3
clotting factors see coagulation factors
cloverleaf skull (Kleeblattschädel) 819, 823
clofentisoxin 228
clubfoot (talipes equinovarus) 757–8,
clonidine
emergency agitation 736
epidural 202, 423, 862, 863
premedication 289, 344
cloning, electronic records 1276
Closed Claims Project, ASA 1153, 1242–3
clotting factors see coagulation factors
cloverleaf skull (Kleeblattschädel) 819, 823
clofentisoxin 228
clubfoot (talipes equinovarus) 757–8,
clonidine
emergency agitation 736
epidural 202, 423, 862, 863
premedication 289, 344
cloning, electronic records 1276
Closed Claims Project, ASA 1153, 1242–3
clotting factors see coagulation factors
cloverleaf skull (Kleeblattschädel) 819, 823
clofentisoxin 228
clubfoot (talipes equinovarus) 757–8,
clonidine
emergency agitation 736
epidural 202, 423, 862, 863
premedication 289, 344
cloning, electronic records 1276
Closed Claims Project, ASA 1153, 1242–3
clotting factors see coagulation factors
cloverleaf skull (Kleeblattschädel) 819, 823
clofentisoxin 228
clubfoot (talipes equinovarus) 757–8,
end-stage renal disease (ESRD)
dialysis 751–3
dialysis catheter placement 753
pathophysiology 694
posterior urethral valves 744
renal transplantation 693, 695–6
see also chronic kidney disease
terminal carbon dioxide (ETCO₂)
common patterns 404, 404
during CPR 260
monitoring with capnography/capnometry
PICU 960–1
energy expenditure
correlation with weight 217, 217
resting (REE) 987
epidural space, developmental changes 420
postoperative behavior changes 1206
enteral feeding
epinephrine 952
epidermolysis bullosa (EB) 1000–1, 1000–1
ephedrine, dosing 1295
epiglottis 303, 304
developmental changes 168, 207, 207
postoperative behavior changes 1206
postanesthesia discharge 335, 366–7, 499
outpatient anesthesia 878–9
operating room environment 500–1
extramural procedures 1236–8
room procedures 1236
extracorporeal life support (ECLS) 971–3
extracorporeal cardiopulmonary resuscitation (E-CPR) 267
extracorporeal membrane oxygenation (ECMO)
EMLA® cream
Evans myopathy 1168
evaporative heat loss 1160, 1161
evrenolimus 680, 681, 682
evidence-based medicine (EBM) 1275, 1277
evoked potentials (EP)
development 125
monitoring 137, 137
sickle cell disease 984
excitation–contraction coupling
immature heart 87
exercise tolerance
after transplantation of great arteries repair 641
Fontan patients 633
EXIT procedure see ex utero intrapartum treatment (EXIT) procedure
exophalms see omphalocoele
extra-pubic infants 497–519
abdominal wall defects 503–6
anesthesia management 335
case study 516–17, 517–18
congenital diaphragmatic hernia 510–12
esophageal atresia and tracheo-esophageal fi stula 506–10
inguinal hernia 502–3, 503
meningomyelocele 512–13
operating room environment 500–1
outpatient anesthesia 878–9
postanesthetic apnea 335, 492, 498–9
postoperative extubation or ventilation 501–2
problems and complications 497–500, 498
see also extra-pubic premature infants
postoperative extubation or ventilation 501–2
problems and complications 497–500, 498
see also extra-pubic premature infants
postoperative extubation or ventilation 501–2
problems and complications 497–500, 498
see also extra-pubic premature infants
glucose-6-phosphate deficiency 1040–1

glucose infusions
cardiopulmonary arrest 265
diabetic patients 222, 532
dosing 1298
hyperkalemia 979
neonates 212
intraoperative 215, 216, 353
older infant/child, intraoperative 220, 353
premature infants 482, 490–1, 491, 492
status epilepticus 977

halothane 174–7
halogenated agents 174–80
hepatic metabolism 564

heart

heart block
complete (CHB) 955
fetal intervention 499
first degree 954–5
second degree 955

heart disease
genetic syndromes 994, 998
perioperative cardiac arrest 1154, 1244

heart-lung transplantation 715
complications 717, 718

heart murmurs
premature infants 485–6
preoperative evaluation 277, 281, 331

heat
heat block 346

heat transfer, internal 1163–4

heat production

heat loss
heat and moisture exchangers (HMEs) 318
helicopter transport 990
heliotropic syndrome 564

idiopathic hypertrophic pyloric stenosis (IHPS) 1271

idiopathic thrombocytopenia purpura (ITP) 1272

idiopathic vein occlusion syndrome 1273

identifying key performance indicators (KPIs) 1274

identifying potential process changes 1275

identifying potential solutions 1275

identifying triggers 1275

ideopathic pulmonary fibrosis 1276

ideopathic thrombocytemia 1277

ideopathic thrombocytopenia 1278

ideopathic thrombocytopenic purpura (ITP) 1279

ideopathic thrombocytopenic purpura (ITP) 1280

ideopathic thrombosis 1281

ideopathic thrombosis 1282

kg

kilotons

kilograms

King’s Fund

Kirkland, C.S. 564

Kirkland, C.S. 565

Kirkland, C.S. 566

Kirkland, C.S. 567

Kirkland, C.S. 568

Kirkland, C.S. 569

Kirkland, C.S. 570

Kirkland, C.S. 571

Kirkland, C.S. 572

Kirkland, C.S. 573

Kirkland, C.S. 574

Kirkland, C.S. 575

Kirkland, C.S. 576

Kirkland, C.S. 577

Kirkland, C.S. 578

Kirkland, C.S. 579

Kirkland, C.S. 580

Kirkland, C.S. 581

Kirkland, C.S. 582

Kirkland, C.S. 583

Kirkland, C.S. 584

Kirkland, C.S. 585

Kirkland, C.S. 586

Kirkland, C.S. 587

Kirkland, C.S. 588

Kirkland, C.S. 589

Kirkland, C.S. 590

Kirkland, C.S. 591

Kirkland, C.S. 592

Kirkland, C.S. 593

Kirkland, C.S. 594

Kirkland, C.S. 595

Kirkland, C.S. 596

Kirkland, C.S. 597

Kirkland, C.S. 598

Kirkland, C.S. 599

Kirkland, C.S. 600

Kirkland, C.S. 601

Kirkland, C.S. 602

Kirkland, C.S. 603

Kirkland, C.S. 604

Kirkland, C.S. 605

Kirkland, C.S. 606

Kirkland, C.S. 607

Kirkland, C.S. 608

Kirkland, C.S. 609

Kirkland, C.S. 610

Kirkland, C.S. 611

Kirkland, C.S. 612

Kirkland, C.S. 613

Kirkland, C.S. 614

Kirkland, C.S. 615

Kirkland, C.S. 616

Kirkland, C.S. 617

Kirkland, C.S. 618

Kirkland, C.S. 619

Kirkland, C.S. 620

Kirkland, C.S. 621

Kirkland, C.S. 622

Kirkland, C.S. 623

Kirkland, C.S. 624

Kirkland, C.S. 625

Kirkland, C.S. 626

Kirkland, C.S. 627

Kirkland, C.S. 628

Kirkland, C.S. 629

Kirkland, C.S. 630

Kirkland, C.S. 631

Kirkland, C.S. 632

Kirkland, C.S. 633

Kirkland, C.S. 634

Kirkland, C.S. 635

Kirkland, C.S. 636

Kirkland, C.S. 637

Kirkland, C.S. 638

Kirkland, C.S. 639

Kirkland, C.S. 640

Kirkland, C.S. 641

Kirkland, C.S. 642

Kirkland, C.S. 643

Kirkland, C.S. 644

Kirkland, C.S. 645

Kirkland, C.S. 646

Kirkland, C.S. 647

Kirkland, C.S. 648

Kirkland, C.S. 649

Kirkland, C.S. 650

Kirkland, C.S. 651

Kirkland, C.S. 652

Kirkland, C.S. 653

Kirkland, C.S. 654

Kirkland, C.S. 655

Kirkland, C.S. 656

Kirkland, C.S. 657

Kirkland, C.S. 658

Kirkland, C.S. 659

Kirkland, C.S. 660

Kirkland, C.S. 661
neonates (cont.)
  upper airway anatomy 303
  see also premature infants; ex-premature infants
  Neo-puff™ 515
neostigmine 193, 196, 568
dosing 193
nephroblastoma see Wilms tumor
neoprogenic rests 161, 749
neurodevelopmental delay 1340
neuroblastoma 726–8, 730
neural tube defects 119–20
neural tube 117–19, 655–6
nephrons, development 160
nephronophthisis (NPH) 166
nephrology, PICU 978–81
neuromonitoring 1207–9
neuromuscular blocking agents (NMBAs) 191–6
neuromuscular blockade monitoring 191–3, 192
neurodevelopmental outcomes 140
neuroleptic analgesia, awake craniotomy 561
neurofibromatosis
neuroendocrine hyperplasia of infancy (NEHI) 118–19
neuroendocrine bodies (NEB), pulmonary 100
neuronal apoptosis, anesthetic-induced 24
neuronal transmission 191
neurofibromatosis 774, 1080–3
  type I 1080–3
  type II 1082–3
neuroleptic analgesia, awake craniotomy 561
neurological complications 1029
  capnographic 476
cardiopulmonary bypass 614
  end-stage renal disease 694
hypoatremia 218, 219
  regional blocks 439–41
sickle cell disease 238, 984
neurological examination 1027
  PICU patients 974
  premature infants 487
  see also cerebral palsy
neurodevelopmental delay see developmental delay
neurodevelopmental outcomes 140
anesthesia and surgery 1202–13
  cerebral effects 543–4
  neonates 1184–5
neurotoxicity 1185–96
  cerebral angiography 930
dosing 1295
  EXIT procedure 449
  open fetal surgery 470
nitroprusside
dosing 1295
  postoperative hypertension 371
nitric oxide (NO) 1192
  inhalation (INO) 297
  ALI/ARDS 971
  bronchopulmonary dysplasia 113
  congenital diaphragmatic hernia 511
  respiratory distress syndrome 478
  pulmonary vasodilation 89–9, 91
neurotoxicity 1192
  methadone as 855
  nociception 122
  neonates 1184–5
  nociceptors 122
  development 122
  termination 123
  maturation of responsiveness 125
  non-invasive ventilation 1340
  asthma 967
  bronchopulmonary dysplasia 108
  cystic fibrosis 524, 528
  PICU 962, 962–3
  postoperative period 316
  see also bilevel positive airway pressure; continuous positive airway pressure
PHACE association 1094–5
phantom pain 865
pharmacodynamics
benzodiazepines 180–1
inhaled anesthetics 176–80
intravenous anesthetics 182, 183, 184–6
local anesthetics 200, 200–2, 421–2, 422
opioids 187, 189, 190
pharmacokinetics
benzodiazepines 180, 181
burn patients 907
inhaled anesthetics 174, 175, 175–6
intravenous anesthetics 181, 181–3, 184, 185
local anesthetics 196–200, 199, 421
muscle relaxants 193, 193–5
opioids 186–7, 188, 189, 190
pharmacology 168–204
analgescics 848–9
local anesthetics 836–9
neuropharmacology 540–4
pharyngeal flap 833, 1295
pharyngoplasty
postoperative management 840–1
see also cleft lip and palate reconstruction
pharynx
anatomy 303–4
development 149–50
anatomy 303–4
see also anatomy
pharmacodynamics
pharmacokinetics
pharmacology 168–204
phase II trials
phase III trials
phase IV trials 48
phenoxybenzamine 729, 1295
pharynx
pharyngeal flap 833, 1295
pharyngeal pouches 301, 302
pharyngoplasty
postoperative management 840–1
see also cleft lip and palate reconstruction
pharynx
anatomy 303–4
development 149–50
developmental anatomy 303–4
see also anatomy
physiology, developmental
Physician Quality Reporting Initiative (PQRI)
physiology, developmental
Pierre–Robin (Robin) sequence (PRS) 820, 997
PKD1 gene 166
PKD2 gene 166
PKHD1 gene 166
polycystic kidney disease 166
polycystins 166
pKa values, local anesthetics 198, 198
PKD1 gene 166
PKD2 gene 166
PKHD1 gene 166
postoperative behavior changes
continuous infusion
development 149–50
anatomy 303–4
see also anatomy
postoperative management 840–1
sinus surgery 786
for priapism 755
dosing 1295
planning, perioperative 274
pKa values, local anesthetics 198,
pilocarpine, neuroprotective effects 1216
platelet function tests 229–30, 1310
platelet function analyzer (PFA-100) 229, 230
closure time 230
platelet function tests 229–30, 1310
platelet-rich plasma 241
transfusion threshold 245
platelet function analyzer (PFA-100) 229, 230
closure time 230
preoperative use 233
transfusion threshold 245
platelet transfusions 245–6, 981, 1298
during liver transplantation 691
indication 245
massive transfusion 246
platelets for 241, 242–3
preoperative infants 488
recipient compatibility 240, 243
septic transfusion reactions 250
volumes administered 245–6
pleural effusions, after Fontan procedure 628,
plexus circumales 150
PLUG concept, congenital diaphragmatic hernia
446
pneumonectomy 577
pneumonia
preoperative infants 484
ventilator-associated (VAP) 988
pneumoperitoneum, laparoscopic surgery
737
pneumothorax
attack-related 400
left
cystic fibrosis, surgical treatment 526
laser-induced 796–7, 407
Pons–Veau–W關’s law 105
cystic kidney disease 166
cystsins 166
polycystins
congenital heart disease 597
premature infants 481
polycystic kidney disease 762, 763
polycystin 166
polymicrogyria 120
polysonnography, sleep 782, 782
Pompe disease 100–3
popliteal nerve block 435–6
pores of Kohn, development 97
porphyria
postaxial acrofacial dysostosis syndrome
portal hypertension 685
cystic fibrosis 526
portal vein, development 141
portocaval shunts, liver transplantation 688
posterior cerebral arteries 127
posterior tibial artery catheters
posterior urethral valves (PUV) 755
postoperative
pharmacodynamics
pharmacokinetics
pharmacology 168–204
analgescics 848–9
local anesthetics 836–9
neuropharmacology 540–4
pharyngeal flap 833, 1295
pharyngeal pouches 301, 302
pharyngoplasty
postoperative management 840–1
see also cleft lip and palate reconstruction
postoperative
pharmacodynamics
pharmacokinetics
pharmacology 168–204
analgescics 848–9
local anesthetics 836–9
neuropharmacology 540–4
pharyngeal flap 833, 1295
pharyngeal pouches 301, 302
pharyngoplasty
postoperative management 840–1
see also cleft lip and palate reconstruction
postoperative
airway pressure
positive end-expiratory pressure (PEEP)
posterior cleft lip and palate reconstruction
posterior cardiomyopathy
posterior cardiomyopathy
posterior fossa tumors 553–5, 554
postoperative ICU management 361
pregnancy
retinopathy of prematurity 483
venous air embolism 549
positive pressure ventilation (PPV)
arterial pressure waveforms 395, 396
congenital cystic lung lesions 578, 579
developing countries 1144
neonatal resuscitation 514–15
oral or nasal airways 309
see also mechanical ventilation
posterior cleft lip and palate reconstruction
posterior fossa tumors 553–5, 554
postoperative ICU management 361
pregnancy
retinopathy of prematurity 483
venous air embolism 549
positive pressure ventilation (PPV)
arterial pressure waveforms 395, 396
congenital cystic lung lesions 578, 579
developing countries 1144
neonatal resuscitation 514–15
oral or nasal airways 309
see also mechanical ventilation
positive pressure ventilation (PPV)
von Willebrand factor (vWF) 224, 234
antigen 230, 1314
assays 230, 234–5
deficiency/qualitative defects 234
developmental changes 228, 228
functional analysis 230
don Willebrand ristocetin cofactor activity 230, 1314
VPS, LLC 949
VSD see ventricular septal defects
V wave 396–7
Wada testing 929
Wake Up Safe Initiative 1245–8
wake-up test
interventional radiology 929
spinal surgery 556, 671–2
wall suction 339–40
MRI suites 934
war, victims of 1141, 1147
warmers
forced air 341–2, 1164
overhead radiant 208
warming
blood products 215, 243
inspired gases 215, 1164
intraoperative 1163–4
intravenous fluids 215, 1163–4
methods
neonatal resuscitation 514
neurosurgical patients 548
operating room 341–2, 1163–4
ICU 372
surface 1164
water
excess, hyponatremia 218
insensible loss see insensible water loss
renal excretion 162, 163
total body 168, 207, 207
see also fluid(s)
Waters, Ralph 17, 20
Waterston shunt 622
Weaver syndrome 1130–1
Weber-Cockayne syndrome see Cockayne syndrome
weight see bodyweight
Wenckebach phenomenon 955
Werding-Hoffmann disease 1112–15
West Nile virus, transmission via transfusion 247–8
wheezing
asthma vs 966
bronchospasm vs 347
outpatient anesthesia 881
preoperative evaluation 335, 347
whey proteins 157–8
whistling face syndrome 773, 1132–5
white blood cell count (WBC) normal neonates 480, 481
reference ranges 1314
septic preterm infants 480
whole blood (WB) 241
collection 240–1
compatibility of recipients 240
transfusion 243–4, 1298
Wilms syndrome (WS) 998–9, 1134–5
balloon dilation of pulmonary arteries 619
facial features 998, 999
Wilms tumor 748–50
abdominal mass 729, 748
associated anomalies 749
case study 416–17, 418
embryologically origin 161
staging system 749
surgical complications 750, 750
wire-guided endobronchial blockers (WEBs) 572, 572
Wisconsin laryngoscope blade 338
Wiskott-Aldrich syndrome 1136–7
withdrawing mechanical ventilation 9
Wolffian duct see mesonephric duct
Wolff-Parkinson-White (WPW) syndrome 954
Wong-Baker pain scale 846, 848
World Federation of Societies of Anaesthesiologists (WFSA) 1140, 1142
World Health Organization (WHO) 50, 1150
Surgical Safety Checklist 1286, 1287
wound dressing changes, burns 904
wound infections, diabetes 221
wrong patient, electronic records 1276
wrong side/site procedures 1245–8
xenon (Xe) 174, 175
neuroprotective effects 1216
neurotoxicity 1194, 1196, 1198
Yale Preoperative Anxiety Scale 284
modified 284, 284
Yankauer suction 339–40
yawning 1159
yolk sac 149, 151–2
young adults 520–38
alcohol and drug misuse 521
chronic diseases 522–34
cigarette smoking 522
pregnancy 522
transition to adult care 522–3
see also adolescents
Yount procedure 768
Zellweger syndrome 1138–9